Items tagged with Medicines
Scientists shed light on action of key TB drug (post)
A new study led by scientists at the University of Birmingham has shed fresh light on how a key front-line drug kills the tuberculosis bacterium.
TB Alliance is honored to accept the Prix Galien Award for Best Pharmaceutical Agent (post)
NEW YORK (October 30, 2020) — At the Prix Galien Awards Ceremony on Thursday, October 29, The Galien Foundation named pretomanid the Best Pharmaceutical Agent of 2019.
Hit movie reveals how a TB drug halts ATP synthesis (post)
Structural data revealing how an anti-tuberculosis drug works could aid efforts to improve therapeutic options for the disease. The findings also uncover aspects of how the drug’s target, the ATP synthase enzyme, operates.
TB Alliance announces first patient dosed with TBAJ-587 in Phase 1 study (post)
NEW YORK (December 15, 2020)—TB Alliance announced that on December 1, 2020 the first dose was administered to a patient as part of a new Phase 1 study of its novel compound TBAJ-587 in healthy adult volunteers. New treatment options are urgently needed, especially as there is growing resistance to available drugs to treat tuberculosis (TB).
Amgen licenses AMG 634, an investigational treatment for TB and leprosy, to Medicines Development for Global Health (post)
THOUSAND OAKS, Calif. and MELBOURNE, Australia, Dec. 22, 2020 -- Amgen (NASDAQ:AMGN) and Medicines Development for Global Health (MDGH), a non-profit biopharmaceutical company, today announced that the companies have entered into a license agreement for AMG 634, a phosphodiesterase type 4 (PDE4) inhibitor being investigated for the treatment of tuberculosis (TB) and erythema nodosum leprosum (ENL), an inflammatory cutaneous and systemic complication of leprosy. The compound is in Phase 2 development with studies led by the Aurum Institute NPC (TB study) and The Leprosy Mission Nepal (ENL study). Amgen had acquired AMG 634 (formerly CC-11050) as part of its acquisition of Otezla® (apremilast) from Celgene in 2019. Under the terms of the agreement, MDGH will assume full responsibility for the further development and commercialization of AMG 634.
Proposing a new drug to treat TB utilizing state-of-the-art computer simulations (post)
The research team of the Department of Computer Science and Engineering at the Toyohashi University of Technology and the Institute of Food Biotechnology and Genomics at the National Academy of Sciences of Ukraine have proposed a new drug to treat tuberculosis (TB), utilizing the state-of-the-art molecular simulations. This drug may inhibit the cell division of Mycobacterium tuberculosis (M. tuberculosis) and suppress its growth. In addition, because this drug acts on the enzymes secreted by M. tuberculosis instead of acting on M. tuberculosis itself, M. tuberculosis has very little chance of mutation and develops no drug resistance. Therefore, it is expected that this drug will lead to a novel drug that will keep its effectiveness for a long time.
Antibiotic could be repurposed and added to TB treatment arsenal (post)
Research has found fidaxomicin, an antibiotic usually used to treat bowel infections, prevents growth of resistant strains of Mycobacterium tuberculosis (MTb) in the lab.
TB Alliance and GSK announce partnership to develop new TB therapeutics (post)
NEW YORK (March 18, 2021) — TB Alliance and GSK have agreed to extend their longstanding collaboration to discover new compounds that can improve the treatment of tuberculosis (TB).
Anti-TB drug can be safely dosed even higher (post)
A considerably higher dose of the anti-tuberculosis drug rifampicin is safe and can also lead to a shorter treatment for tuberculosis and less resistance. This is what researchers from Radboud university medical center in Nijmegen write in a recent publication. With this they complete a year-long search for the right dosing of an old drug against tuberculosis that appears to be the key drug.
Astellas and TB Alliance enter into a new collaborative research agreement to identify lead compounds for the treatment of TB (post)
TOKYO and NEW YORK (March 31, 2021) — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and TB Alliance (President and CEO: Mel Spigelman, M.D.), a non-profit organization dedicated to finding faster-acting and affordable drug regimens to fight tuberculosis (TB) today announced that they have entered into a new collaborative research (“Hit-to-Lead PJ”) agreement to identify lead compounds for the treatment of TB.
Page 11 of 19 · Total posts: 0
←First 10 11 12 Last→